BioSpace News Archive

Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced today that it has closed on its Series A financing led by a non-disclosed major strategic investor along with a significant investment from ShangBay Capital, an early stage medical device investor as well as other investors including Mayo Clinic.

From Parkinson’s to schizophrenia and depression, Modality’s multimodal solution – the first of its kind – is being used by leading research institutions globally to monitor, diagnose, and expedite the treatment of patients in clinic and remotely.

MicroMGx, Inc., a life sciences company dedicated to making high-throughput natural product discovery achievable, today announced an expanded agreement focused on accelerating natural products discovery with pure-play global agriculture company Corteva Agriscience

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in four virtual investor conferences in September.

Ziopharm Oncology, Inc., announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences

Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2022 on September 8, 2021

Prothena Corporation plc, a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced that members of its senior management team will participate in the following September investor conferences

Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer.

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 89,000 shares of Akebia’s common stock on August 31, 2021, as inducements material to each such employee’s entering into employment with Akebia.